echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Treat chronic hepatitis B! GSK antisense oligonucleotide drug approved for clinical use

    Treat chronic hepatitis B! GSK antisense oligonucleotide drug approved for clinical use

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Sunshine

    August 12, CDE official website shows, GlaxoSmithKline antisense oligonucleotides GSK3228836 injection drugs in clinical trials apply the State Food and Drug Administration approval for the treatment of chronic hepatitis


    Source: PharmaGo

    Chronic hepatitis B is a chronic disease in which hepatitis B virus (HBV) continues to be infected for more than 6 months, and the liver undergoes varying degrees of inflammatory necrosis (or) fibrosis


    Nucleoside and nucleoside analog drugs currently used to treat hepatitis B can inhibit the hepatitis B virus, but cannot completely remove the virus from the body


    GSK3228836 is an antisense oligonucleotide that can specifically recognize the mRNA used to express viral antigens (pathogenic proteins) in liver cells infected with HBV, and inactivate viral mRNAs by mobilizing the liver’s own enzymes to inhibit viral proteins HBsAg levels in order to achieve the functional purpose of curing hepatitis B


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.